2011-05-16 |
Heberprovac Study |
CIGB |
Registered |
2011-05-16 |
TS-FARMEV Study |
CIGB |
Registered |
2011-05-17 |
CERVISEG-300-I Study |
CIGB |
Registered |
2011-04-28 |
Alum Phospate Adjuvated QuimiHib® Vaccine Clinical Study. |
CIGB |
Registered |
2011-04-29 |
CENTAURO Study |
CIGB |
Registered |
2011-04-29 |
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 2-4-6 months. |
CIGB |
Registered |
2011-04-30 |
NEUVITAL V Study |
CIGB |
Registered |
2011-04-30 |
Change in Manufacture Process of Heberbiovac HB vaccine. |
CIGB |
Registered |
2011-04-27 |
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 6-10-14 weeks. |
CIGB |
Registered |
2009-02-12 |
Evaluation of the antiinflammatory effect of the Vimang® cream in patients with Dermatitis chronic disease. |
CQF |
Registered |
2009-02-27 |
Effect of the supplementation with Vimang ® on indicators of oxidative stress in young people with Diabetes Mellitus type 1. |
CQF |
Registered |
2009-02-27 |
Extract of Mangifera indica L. (Vimang®)- Third age- Phase II. |
CQF |
Registered |
2009-03-13 |
Extract of Mangifera indica L. (Vimang®)-Ischemic Stroke |
CQF |
Registered |
2009-03-13 |
Evaluation of the neuroprotector effect of an extract of stem bark of Mangifera indica L. (Vimang®) in patient with Spinocerebellar Hereditary Ataxia Type 2 |
CQF |
Registered |
2010-12-03 |
1E10 anti-idiotype vaccine, metastatic colon, phase II. |
CIM |
Registered |
2010-12-24 |
Toxicological evaluation of the humanized Anti-CD6 MAb T1h in Rheumatoid Arthritis Patients |
CIM |
Registered |
2010-12-27 |
1E10 anti-idiotype vaccine, metastatic breast cancer, phase II |
CIM |
Registered |
2010-12-28 |
Anti-idiotype 1E10 vaccine in advanced non- small cell lung (NSCLC) patients |
CIM |
Registered |
2010-12-28 |
Anti-idiotype 1E10 vaccine in the treatment of patients with small cell lung (SCLC) patients |
CIM |
Registered |
2010-12-28 |
h-R3 MaB and radiotherapy in pediatric patients with intrinsic diffuse astrocytomas of brain stem, phase II. |
CIM |
Registered |